ArticleClinical & experimental metastasis2024

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.

Levent Mutlu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.